Search Results - "Ferguson, Murdo"

Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

Authors: Mitha, Essack Ferguson, Murdo Wilhase, Agatha Cathrine et al.

Source: Clinical Infectious Diseases. 5/15/2026, Vol. 82 Issue 5, pe1093-e1103. 11p.

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age.

Authors: Ferguson, Murdo Schwarz, Tino F Núñez, Sebastián A et al.

Source: Clinical Infectious Diseases. 10/15/2024, Vol. 79 Issue 4, p1074-1084. 11p.

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.

Authors: Hermida, Nerea Ferguson, Murdo Leroux-Roels, Isabel et al.

Source: Journal of Infectious Diseases. 8/15/2024, Vol. 230 Issue 2, pe353-e362. 10p.

Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.

Authors: Leroux-Roels, Isabel Huang, Grace Ferguson, Murdo et al.

Source: New England Journal of Medicine. 5/7/2026, Vol. 394 Issue 18, p1803-1813. 11p.

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial.

Authors: Madan, Anuradha Ferguson, Murdo Rheault, Paul et al.

Source: Vaccine. Apr2017, Vol. 35 Issue 15, p1865-1872. 8p.

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.

Authors: Madan, Anuradha Ferguson, Murdo Sheldon, Eric et al.

Source: Vaccine. Mar2017, Vol. 35 Issue 10, p1431-1439. 9p.

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants.

Authors: Scheifele, David W. Ferguson, Murdo Predy, Gerald et al.

Source: Vaccine. Apr2015, Vol. 33 Issue 16, p1897-1900. 4p.

Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant.

Authors: Ferguson, Murdo Risi, George Davis, Matthew et al.

Source: Journal of Infectious Diseases. 3/1/2012, Vol. 205 Issue 5, p733-744. 12p.

Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years.

Authors: Mayer, Erick F Falsey, Ann R Clark, Rebecca et al.

Source: Clinical Infectious Diseases. 12/15/2025, Vol. 81 Issue 6, pe708-e716. 9p.

Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.

Authors: Galgani, Ilaria Annaratone, Margherita Casula, Daniela et al.

Source: Respiratory Research. 5/4/2022, Vol. 23 Issue 1, p1-13. 13p.

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.

Authors: Lazaar, Aili L. Miller, Bruce E. Donald, Alison C. et al.

Source: Respiratory Research. 6/12/2020, Vol. 21 Issue 1, p1-10. 10p. 1 Diagram, 5 Charts, 1 Graph.

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.

Authors: Madan, Anuradha Segall, Nathan Ferguson, Murdo et al.

Source: Journal of Infectious Diseases. 12/1/2016, Vol. 214 Issue 11, p1717-1727. 11p.

Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.

Authors: Boutry, Céline Hastie, Andrew Diez-Domingo, Javier et al.

Source: Clinical Infectious Diseases. 4/15/2022, Vol. 74 Issue 8, p1459-1467. 9p.

A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.

Authors: Vandermeulen, Corinne Leroux-Roels, Isabel Vandeleur, James et al.

Source: Vaccine. Oct2021, Vol. 39 Issue 45, p6628-6636. 9p.

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.

Authors: Folschweiller, Nicolas Behre, Ulrich Dionne, Marc et al.

Source: Journal of Infectious Diseases. 6/1/2019, Vol. 219 Issue 11, p1799-1803. 5p.

Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.

Authors: Nolan, Terry Santolaya, Maria Elena de Looze, Ferdinandus et al.

Source: Vaccine. Feb2019, Vol. 37 Issue 9, p1209-1218. 10p.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.

Authors: Maréchal, Céline Lal, Himal Heineman, Thomas C et al.

Source: Vaccine. Jul2018, Vol. 36 Issue 29, p4278-4286. 9p.

Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278–4286].

Authors: Maréchal, Céline Lal, Himal Poder, Airi et al.

Source: Vaccine. Feb2019, Vol. 37 Issue 9, p1252-1253. 2p.

Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.

Authors: Ferguson M Schwarz TF Núñez SA et al.

Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2579335. Date of Electronic Publication: 2025 Nov 05.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults.

Authors: Ferguson M Murray A Pliamm L et al.

Source: Vaccine: X [Vaccine X] 2024 Apr 27; Vol. 18, pp. 100494. Date of Electronic Publication: 2024 Apr 27 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101748769 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-1362 (Electronic) Linking ISSN: 25901362 NLM ISO Abbreviation: Vaccine X Subsets: PubMed not MEDLINE